1. HOME
2. Research Insight
3. NVIDIA Corporation (US) and Exscientia (UK) are Leading Players in the Artificial Intelligence in Drug Discovery Market

The artificial intelligence (AI) in drug discovery market is projected to reach USD 4.9 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 40.2% during the forecast period. Growth in this market is primarily driven by the need to accelerate process and timeline and reduce costs of drug development and discovery and growing number of cross-industry collaborations and partnerships. The substantial upsurge in accessible biomedical data, including genomics, proteomics, and chemical architectures, has increased the the utilization of AI technologies to extract valuable insights. AI modalities, notably machine learning and deep learning, demonstrate proficiency in handling and dissecting this extensive dataset. However, the lack of suitable datasets to feed ai models and lack of access to proprietary databases are expected to hamper the growth of this market during the forecast period to a certain extent.

The prominent players in artificial intelligence (AI) in drug discovery market are NVIDIA Corporation (US), Exscientia (UK), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft Corporation (US), Google (US), Atomwise Inc. (US), Illumina, Inc. (US), NuMedii, Inc. (US), XtalPi Inc. (US), Iktos (France), Tempus Labs (US), Deep Genomics, Inc. (Canada), Verge Genomics (US), BenchSci (Canada), Insitro (US), Valo Health (US), BPGbio, Inc. (US), IQVIA Inc (US), Labcorp (US), Tencent Holdings Limited (China), Predictive Oncology, Inc. (US), Celsius Therapeutics (US), CytoReason (Israel), Owkin, Inc. (US), Cloud Pharmaceuticals (US), Evaxion Biotech (Denmark), Standigm (South Korea), BIOAGE (US), Envisagenics (US), and Aria Pharmaceuticals, Inc. (US). These companies adopted both organic and inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to strengthen their market presence in the artificial intelligence (AI) in drug discovery market.

To know about the assumptions considered for the study download the pdf brochure

NVIDIA CORPORATION (US)

NVIDIA Corporation designs and develops graphics processing units (GPUs) and delivers value to consumers through personal computer (PC), mobile, and cloud architectures. The company focuses on developing deep learning, machine learning, and various other AI technologies. The compnay's products are used in a wide range of industries, including architecture, engineering, construction & operations; automotive; consumer internet; cybersecurity; energy; financial services; healthcare and life sciences; higher education; game development; manufacturing; media and entertainment; us public sector; restaurants; retail and CPG; robotics; smart cities & spaces; supercomputing; telecommunications; and transportation. NVIDIA Corporation operates through two reportable segments—Graphics and Compute & Networking. Nvidia GPUs are used to power AI workloads in drug discovery, such as molecular modeling, simulation, and machine learning. Nvidia's AI software includes development tools, libraries, and frameworks that can be used to build and deploy AI applications for drug discovery. Nvidia Clara Discovery is a software suite that provides a comprehensive set of tools for AI-powered drug discovery. NVIDIA Corporation has more than 50 offices worldwide spread across the Americas, Asia, and Europe. In July 2023, NVIDIA Corporation would invest USD 50 million in Recursion Pharmaceuticals to accelerate the development of AI models for drug discovery. The partnership aims to train AI models using Recursion's vast biological and chemical datasets on Nvidia's cloud platform.

EXSCIENTIA (UK)

Exscientia is an AI-driven small-molecule drug discovery and design company. Its product pipeline demonstrates the ability to rapidly translate scientific concepts into precision-designed therapeutic candidates. The company designed and developed an end-to-end solution of AI and experimental technologies for target identification, drug candidate design, translational models, and patient selection. Exscientia's products and services are used by pharmaceutical companies and biotech startups to accelerate the drug discovery process. The company also partners with academic researchers to develop new AI-powered drug discovery technologies. The company manages its operations as a single segment. Exscientia's AI-powered drug discovery platform is a proprietary platform uses artificial intelligence to design and develop new drugs. The platform integrates a variety of data sources, including chemical data, biological data, and clinical data, to identify new drug targets and to design new drug candidates. Exscientia works in collaboration with pharmaceutical companies such as GSK, Sanofi, and Roche. The company has offices in the UK, the US, and Japan. In September 2023, Exscientia entered into a collaboration with Merck KGaA focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilize Exscientia’s AI-driven precision drug design and discovery capabilities while leveraging Merck KGaA’s disease expertise in oncology and neuroinflammation, clinical development capabilities and global footprint.

Related Reports:

Artificial Intelligence in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]